| 000 | 01635 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515174609.0 | ||
| 264 | 0 | _c20091001 | |
| 008 | 200910s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.24473 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWeber, Jeffrey S | |
| 245 | 0 | 0 |
_aRandomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. _h[electronic resource] |
| 260 |
_bCancer _cSep 2009 |
||
| 300 |
_a3944-54 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCytokines _xanalysis |
| 650 | 0 | 4 |
_aDacarbazine _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOligodeoxyribonucleotides _xadministration & dosage |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aZarour, Hassan | |
| 700 | 1 | _aRedman, Bruce | |
| 700 | 1 | _aTrefzer, Uwe | |
| 700 | 1 | _aO'Day, Steven | |
| 700 | 1 | _avan den Eertwegh, Alfons J M | |
| 700 | 1 | _aMarshall, Ernest | |
| 700 | 1 | _aWagner, Stefan | |
| 773 | 0 |
_tCancer _gvol. 115 _gno. 17 _gp. 3944-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.24473 _zAvailable from publisher's website |
| 999 |
_c18955197 _d18955197 |
||